Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer

This study tests a radiation approach called "moderate hypofractionated boost" — delivering radiation to the prostate in fewer, slightly larger doses — combined with pelvic radiation, for men with high-risk prostate cancer. The goal is to see whether this approach is as effective and safe as standard radiation schedules. **You may be eligible if...** - You are over 18 years old with a confirmed diagnosis of prostate adenocarcinoma (prostate cancer) - You have high-risk or locally advanced prostate cancer by NCCN criteria (e.g., tumor stage cT3+, Gleason grade group 4+, or PSA over 20 ng/mL, or cancer in nearby lymph nodes) - Your cancer has not spread to distant parts of the body (M0) - Your general health is good (ECOG 0–1) **You may NOT be eligible if...** - You have had prior pelvic radiation - You have medical contraindications to radiation therapy Talk to your doctor to see if this trial is right for you.